Priabprat Jansem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Priabprat Jansem has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Noppachai Siranart
Division of Gastroenterology, Hepatology and Endoscopy, Brigham & Women's Hospital, Boston, Massachusetts, USA
3 shared publications - Patavee Pajareya
Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
3 shared publications - Abbas Firras Almuala
International NIMETOX Center, Sichuan Provincial Center for Mental Health, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China
2 shared publications - Asara Vasupanrajit
Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publications - Elizabet Dzhambazova
Department of Social Medicine and Public Health, Faculty of Public Health, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria
2 shared publications - Michael Maes
Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publications
Latest Publications
- 8 November 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (3) , 469-475
Efficacy and safety of anakinra for acute calcium pyrophosphate deposition disease flare: a systematic review and meta-analysis
Objective: Calcium pyrophosphate deposition disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an interleukin-1 inhibitor, is a promising alternative. We aimed to evaluate the efficacy and safety of anakinra in acute CPPD flares. Methods: We systematically searched studies from MEDLINE, EMBASE, and the Cochrane Database up until August 2024. The primary outcome was a positive treatment response between Day 3 and Day 5 after anakinra initiation. Secondary outcomes included changes in pain ratings assessed by the visual analogue scales (VAS), C-reactive protein (CRP) levels, tender joint counts (TJCs), swollen joint counts (SJCs), and steroid usage. Results: Six studies were included in our meta-analysis: five observational studies and one randomized controlled trial. A total of 84 patients were included in our analysis. Subjective physician assessments of clinical response were reported in all studies with a combined positive treatment response rate of 76% (95% CI: 61–86, I2 = 0%). Our pooled analysis also showed a significant reduction of VAS scores by 48.12 mm (95% CI: 53.21–43.03, I2 = 0%) and CRP levels by 62.09 mg/L (95% CI: 97.74–26.44, I2 = 77%) from baseline. Reductions of TJC and SJC were also demonstrated: 4.86 (95% CI: 5.48–4.23, I2 = 0%) and 3.65 (95% CI: −12.53 to 5.22, I2 = 54%), respectively. Adverse reactions included injection site reaction, rash, bacterial pneumonitis, and neutropenia. Conclusions: Anakinra is a promising alternative treatment for patients with acute CPPD flare as it showed desirable clinical responses and a favourable safety profile.
- 8 November 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (3) , 469-475
Efficacy and safety of anakinra for acute calcium pyrophosphate deposition disease flare: a systematic review and meta-analysis
Objective: Calcium pyrophosphate deposition disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an interleukin-1 inhibitor, is a promising alternative. We aimed to evaluate the efficacy and safety of anakinra in acute CPPD flares. Methods: We systematically searched studies from MEDLINE, EMBASE, and the Cochrane Database up until August 2024. The primary outcome was a positive treatment response between Day 3 and Day 5 after anakinra initiation. Secondary outcomes included changes in pain ratings assessed by the visual analogue scales (VAS), C-reactive protein (CRP) levels, tender joint counts (TJCs), swollen joint counts (SJCs), and steroid usage. Results: Six studies were included in our meta-analysis: five observational studies and one randomized controlled trial. A total of 84 patients were included in our analysis. Subjective physician assessments of clinical response were reported in all studies with a combined positive treatment response rate of 76% (95% CI: 61–86, I2 = 0%). Our pooled analysis also showed a significant reduction of VAS scores by 48.12 mm (95% CI: 53.21–43.03, I2 = 0%) and CRP levels by 62.09 mg/L (95% CI: 97.74–26.44, I2 = 77%) from baseline. Reductions of TJC and SJC were also demonstrated: 4.86 (95% CI: 5.48–4.23, I2 = 0%) and 3.65 (95% CI: −12.53 to 5.22, I2 = 54%), respectively. Adverse reactions included injection site reaction, rash, bacterial pneumonitis, and neutropenia. Conclusions: Anakinra is a promising alternative treatment for patients with acute CPPD flare as it showed desirable clinical responses and a favourable safety profile.
- 22 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-17
Diagnostic accuracy of anti-carbamylated protein antibodies in rheumatoid arthritis: a systematic review and meta-analysis
Anti-carbamylated protein (anti-CarP) antibodies have emerged as novel serologic markers in rheumatoid arthritis (RA). This meta-analysis aimed to assess t
- 22 September 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (10) , 1-17
Diagnostic accuracy of anti-carbamylated protein antibodies in rheumatoid arthritis: a systematic review and meta-analysis
Anti-carbamylated protein (anti-CarP) antibodies have emerged as novel serologic markers in rheumatoid arthritis (RA). This meta-analysis aimed to assess t
- Open Access
- 13 June 2025
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 25 (4) , 207-217
Natural courses of atrial fibrillation following cryptogenic stroke: A systematic review and meta-analysis
- 13 June 2025
- Published by Elsevier in Indian Pacing and Electrophysiology Journal
- Vol. 25 (4) , 207-217
Open AccessNatural courses of atrial fibrillation following cryptogenic stroke: A systematic review and meta-analysis
- 8 January 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 169, 106005
Increased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression
- 8 January 2025
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 169, 106005
Increased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression
- Open Access
Increased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression
Background Major depressive disorder (MDD) and bipolar disorder (BD) often coexist with metabolic syndrome. Both are linked to increased atherogenicity and a higher risk of cardiovascular diseases. Objectives This meta-analysis seeks to evaluate the relationship between atherogenic indices and mood disorders (MDD/BD), while identifying the most effective atherogenic biomarkers for mood disorders. Methods This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched electronic databases, including PubMed, Google Scholar, and Web of Science, for articles published up to August 1, 2024. Results In this meta-analysis, 85 eligible studies (14 on BD and 71 on MDD) were included, covering 70,856 participants: 18,738 patients and 52,118 healthy controls. Patients with mood disorders showed significant increases (p < 0.001) in the Castelli Risk Index 2 (CRI2), Atherogenic Index of Plasma (AIP), and (triglyceride or TG + low-density lipoprotein + very low-density lipoprotein)/(high-density lipoprotein cholesterol or HDL + Apolipoprotein A or ApoA) ratio, but not CRI1 and ApoB/ApoA ratio. Significant lower HDL and lecithin: cholesterol acyltransferase activity, and higher TG levels were observed in mood disordered patients compared with controls. There were no significant differences between MDD and BD patients. Most included studies lacked the most essential information on the inclusion and exclusion of important confounders. Conclusions AIP is the most effective atherogenicity index for mood disorders. Regular lipid profiling and metabolic syndrome screening are crucial in mood disorders. Early intervention with lipid-lowering therapies is recommended to prevent the worsening of atherogenicity and disease progression.
Open AccessIncreased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression
Background Major depressive disorder (MDD) and bipolar disorder (BD) often coexist with metabolic syndrome. Both are linked to increased atherogenicity and a higher risk of cardiovascular diseases. Objectives This meta-analysis seeks to evaluate the relationship between atherogenic indices and mood disorders (MDD/BD), while identifying the most effective atherogenic biomarkers for mood disorders. Methods This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched electronic databases, including PubMed, Google Scholar, and Web of Science, for articles published up to August 1, 2024. Results In this meta-analysis, 85 eligible studies (14 on BD and 71 on MDD) were included, covering 70,856 participants: 18,738 patients and 52,118 healthy controls. Patients with mood disorders showed significant increases (p < 0.001) in the Castelli Risk Index 2 (CRI2), Atherogenic Index of Plasma (AIP), and (triglyceride or TG + low-density lipoprotein + very low-density lipoprotein)/(high-density lipoprotein cholesterol or HDL + Apolipoprotein A or ApoA) ratio, but not CRI1 and ApoB/ApoA ratio. Significant lower HDL and lecithin: cholesterol acyltransferase activity, and higher TG levels were observed in mood disordered patients compared with controls. There were no significant differences between MDD and BD patients. Most included studies lacked the most essential information on the inclusion and exclusion of important confounders. Conclusions AIP is the most effective atherogenicity index for mood disorders. Regular lipid profiling and metabolic syndrome screening are crucial in mood disorders. Early intervention with lipid-lowering therapies is recommended to prevent the worsening of atherogenicity and disease progression.
- 12 March 2024
- Published by Wiley in European journal of pain
- Vol. 28 (8) , 1402-1410
A SUNCT‐like headache associated with lateral pontine infarction – case series and systematic review
Background and Aim: Short‐lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and autonomic symptoms (SUNA) are trigeminal autonomic cephalalgias (TACs). The study explores the potential association between SUNCT/SUNA‐like headaches and lateral pontine infarctions.Methods: Case series and systematic review.Results: We present three cases diagnosed with SUNCT following lateral pontine infarction on magnetic resonance imaging (MRI), along with a review of these cases and 10 others from the literature.Discussion and Conclusion: This review suggests a connection between SUNCT/SUNA‐like symptoms and lateral pontine infarctions. The section also delves into the anatomy and pathophysiology of these symptoms, proposing a mechanism involving neural pathway remodelling in the lateral brainstem.
- 12 March 2024
- Published by Wiley in European journal of pain
- Vol. 28 (8) , 1402-1410
A SUNCT‐like headache associated with lateral pontine infarction – case series and systematic review
Background and Aim: Short‐lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and autonomic symptoms (SUNA) are trigeminal autonomic cephalalgias (TACs). The study explores the potential association between SUNCT/SUNA‐like headaches and lateral pontine infarctions.Methods: Case series and systematic review.Results: We present three cases diagnosed with SUNCT following lateral pontine infarction on magnetic resonance imaging (MRI), along with a review of these cases and 10 others from the literature.Discussion and Conclusion: This review suggests a connection between SUNCT/SUNA‐like symptoms and lateral pontine infarctions. The section also delves into the anatomy and pathophysiology of these symptoms, proposing a mechanism involving neural pathway remodelling in the lateral brainstem.